Breaking News

Rosa & Co. Acquires Entelos Service Business

By Kristin Brooks | January 23, 2014

Expands presence in systems pharmacology market

Rosa & Co. LLC, a drug development consulting firm, has acquired the consulting service business of Entelos Holdings, Inc., which conducts mechanistic, physiologic, in silico modeling projects for customers for pharmaceutical research and development. The acquisition expands Rosa's presence in quantitative systems pharmacology and modeling and simulation research services and adds expertise in cardiovascular, immunology, and metabolism biology, and human nutrition.
 
The acquisition also allows Entelos' clients to access Rosa's PhysioPD Research Platforms, which employ a user-friendly, open-architecture modeling and simulation system that is interoperable with commonly used third-party software.
 
"We are thrilled to further strengthen our expertise in these key areas, and have the opportunity to offer our proven approach to an expanded client base,” said chief executive officer of Rosa, Ron Beaver, Ph.D."
  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems